Published DateClear

Start Date

End Date

Category

• Pipeline3

Organizations

• Bausch + Lomb70
• Eyes On Eyecare54
• Alcon, Inc.49
• American Optometric Association38
• Harrow32
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Aldeyra Therapeutics21
• Genentech19

Tags

• Retina3
• Stargardt Disease2
• Clinical Trials2
• AMD1
• FDA1
• Geographic Atrophy1
• New Drug Application1
• Visual Acuity1

• Organizations: Belite Bio✕

Clear all

Pipeline

Belite Bio begins rolling NDA submission of oral tinlarebant for Stargardt

Full submission planned for Q2 2026, once-daily tablet has potential to become the first-ever treatment approved for this patient base. 

Pipeline

Belite Bio reports phase 3 topline data on oral tinlarebant for Stargardt disease

DRAGON study is evaluating the once-daily tablet for reducing lesion growth among adolescent patients over a 24-month period.

Pipeline

Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant

Also under clinical development for Stargardt disease, the once-daily tablet is under evaluation for its efficacy in slowing atrophic lesion growth.